Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer

(TheNewswire)

New CFO appointment strengthensVentripoint’s leadership team and supports global rollout ofAI-powered VMS+™ cardiac imaging platform.

Toronto, Ontario – TheNewswire - December 3, 2025 -Ventripoint Diagnostics Ltd. (" Ventripoint ",“ VPT ” or the " Company "), (TSXV:VPT; OTC:VPTDF) a leaderin AI-enhanced cardiac imaging solutions, today announced theappointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer(“ CFO ”), effective immediately. Thisappointment represents an important step in strengtheningVentripoint’s leadership team as the Company embarks on its newcommercial strategic vision and transitions into its growthphase.

Mr. Swetlow brings extensive senior management,financial and public company leadership experience from various rolesacross high-growth medical technology and innovative life sciencecompanies, including Sernova, Ondine, Protox, HealthPricer, One PersonHealth, QLT and Xillix, with a track record of building and executingrobust capital markets strategies; company scale up, product launchand commercialization strategies success; driving and evolvingfinancial systems, reporting, and operational performance for nextstage growth; strategic relationship management; and enhancingcorporate governance. His broad expertise will be instrumental topositioning VPT to achieve the next stage of VMS+ platform marketadoption success and expansion abroad.

“This is a pivotal moment for Ventripoint,” saidHugh MacNaught, President & CEO of Ventripoint Diagnostics.“David’s leadership will play a vital role as we execute on arefreshed commercial strategy designed to scale our technology andplatform, strengthen our global partnerships, and position the companyfor new markets and revenue growth.

As Ventripoint moves into this next stage, the Companyalso extends its appreciation to Jimmy Jeon, who has resigned as CFOand Marelli Services for their valuable support to date. Theircontributions have helped provide stability and continuity through aperiod of important transition.

As CFO, Mr. Swetlow will oversee financial strategy,capital markets, financial reporting and operations, working closelywith the executive team and Board of Directors as VPT advancescommercialization efforts in the U.S., Canada, Europe, the UK, andother priority markets.

“The VMS+™ technology platform stands at theforefront of cardiac imaging innovation, harnessing and leveraging theconvergence of AI with imaging diagnostics to enable what hasn’tpreviously been readily accomplishable cost effectively in thehealthcare ecosystem, nor in a near to real-time manner to enhancecare and reduce the anxious wait times for at-risk cardiac patients tofind out further answers” said Mr. Swetlow. “I am excited to joinVentripoint at this critical juncture to evolve the financial andcommercial foundations needed to scale and make this technologyglobally available for current and expanded indications.”

This appointment represents another foundational stepin building a high-performance leadership team capable of guiding VPTthrough its scale up phase. With a renewed commercial focus and arapidly growing global interest in the Company’s VMS+ cardiacimaging solution, the addition of an experienced public company lifesciences industry CFO strengthens Ventripoint’s ability to deliveron its strategic priorities and realize on opportunities ahead.

The Board of Directors has awarded Mr. Swetlow1,000,000 options exercisable at $0.11 with a term of 10 years andvesting over 12 months.

In other news, the Company wishes to correct the newsrelease of September 3, 2025 as the insider reported to have invested$105,000 has been determined not to be an insider of thecompany.

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leaderin the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary Knowledge Based Reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+™ is versatileand can be used with all ultrasound systems from any vendor supportedby regulatory market approvals in the U.S., Europe, and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company'smost recent annual management's discussion and analysis that isavailable on the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in thisnews release are expressly qualified by this cautionary statement. Theforward-looking statements and information contained in this newsrelease are made as of the date hereof and the Company undertakes noobligation to update publicly or revise any forward-looking statementsor information, whether as a result of new information, future eventsor otherwise, unless so required by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.